WHO ICTRP trial
A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and…
EUCTR2021-001722-21-DE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2021-001722-21-DE |
|---|---|
| Public title | A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma |
| Scientific title | MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition - MONETTE |
| Primary sponsor | AstraZeneca AB |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Canada;Belgium;United States;Korea, Republic of;Poland;United Kingdom;Italy;Australia;France;Germany;Spain |
| Conditions | Unresectable or Advanced Melanoma MedDRA version: 21.1 Level: LLT Classification code 10025655 Term: Malignant melanoma of skin System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA… |
| Interventions | Product Name: Ceralasertib 120 mg Product Code: AZD6738 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralasertib CAS Number: 1352226-88-0 Current Sponsor code: AZD6738 Concentration unit: mg milligram(s) Concentration type… |
| Registration date | Jun 9, 2021 |
| Target size | 195 |
| Secondary IDs | D533AC00001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: